Review
Medicine, General & Internal
Karel Dandurand, Dalal S. Ali, Aliya A. Khan
Summary: Primary hyperparathyroidism is the most common cause of hypercalcemia in outpatient settings, with most patients being asymptomatic or presenting with non-specific signs. Recent guidelines recommend surgery for patients under 50 years old with significant hypercalcemia, impaired renal function, renal stones, or osteoporosis. Medical interventions, such as optimizing calcium and vitamin D intake and using cinacalcet, can be considered for patients not undergoing surgery. The impact of medical treatment on fracture risk reduction should be a focus of future research.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Rebecca K. Dirkes, Nathan C. Winn, Thomas J. Jurrissen, Dennis B. Lubahn, Victoria J. Vieira-Potter, Jaume Padilla, Pamela S. Hinton
Summary: The study found that in male mice, ERKO has a positive impact on bone density, with exercise having little effect. ERKO has a negative impact on cortical geometry, but exercise can partially reverse this effect. Neither ERKO nor exercise have an effect on sclerostin expression.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Medicine, General & Internal
Arkadiusz Zygmunt, Kinga Krawczyk-Rusiecka, Elzbieta Skowronska-Jozwiak, Katarzyna Wojciechowska-Durczynska, Ewa Glowacka, Zbigniew Adamczewski, Andrzej Lewinski
Summary: The study found that recombinant human TSH (rhTSH) has an impact on the concentrations of sclerostin and other bone markers, with a significant increase in TSH concentration leading to decreases in sclerostin, osteocalcin, and beta-CrossLaps levels. Additionally, baseline PTH, age, and creatinine concentrations can affect the degree of TSH increase.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Endocrinology & Metabolism
Jakob Starup-Linde, Simon Lykkeboe, Aase Handberg, Peter Vestergaard, Pernille Hoyem, Jesper Fleischer, Troels Krarup Hansen, Per Logstrup Poulsen, Esben Laugesen
Summary: In this study, individuals with T2D showed lower levels of bone turnover markers compared to controls, with s-CTX and s-P1NP being negatively associated with glycemic variability. Specifically, s-CTX was negatively associated with both MAGE and dawn glucose levels, while s-P1NP was only negatively associated with dawn glucose levels. Further research is needed to explore the impact of reducing glycemic variability on bone turnover markers.
Article
Orthopedics
Anna Matuszewska, Lukasz Matuszewski, Magdalena Jaszek, Pawel Polak, Szymon Stec
Summary: This study found that the use of bisphosphonate-enriched cement with Pamifos(R) after total knee arthroplasty can reduce the levels of bone turnover markers and cytokines, and may help to decrease the risk of osteoporotic fractures and aseptic revisions.
INTERNATIONAL ORTHOPAEDICS
(2022)
Article
Endocrinology & Metabolism
Christian Meier, Richard Eastell, Dominique D. Pierroz, Nancy E. Lane, Nasser Al-Daghri, Atsushi Suzuki, Nicola Napoli, Ambrish Mithal, Marlene Chakhtoura, Ghada El-Hajj Fuleihan, Serge Ferrari
Summary: This review provides a summary of current data on biochemical markers in relation to bone fragility and fracture risk in diabetes. The results show that although bone resorption and bone formation markers are not effective predictors of fracture risk in diabetes, osteoporosis drugs have similar effects on bone turnover markers in both diabetics and nondiabetics, resulting in reduced fracture risk. Other biochemical markers related to bone and glucose metabolism, such as sclerostin, glycated hemoglobin A(1c), and inflammatory markers, as well as hormones like insulin-like growth factor-1 and calciotropic hormones, are also associated with bone mineral density and fracture risk in diabetes. HbA(1c) levels appear to be the most reliable estimate of fracture risk, while bone turnover markers can be used to monitor the effects of antiosteoporosis therapy.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
Yongquan Gao, Xiaochen Liu, Yuan Gu, Deye Song, Muliang Ding, Lele Liao, Junjie Wang, Jiangdong Ni, Guangxu He
Summary: Bisphosphonates do not significantly affect fracture healing time in fracture patients, but they do increase bone density, prevent osteoporosis, and inhibit both bone resorption and formation markers. Early application of bisphosphonates after injury in the appropriate patient population should be considered.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Review
Endocrinology & Metabolism
Elena Tsourdi, M. Carola Zillikens, Christian Meier, Jean-Jacques Body, Elena Gonzalez Rodriguez, Athanasios D. Anastasilakis, Bo Abrahamsen, Eugene McCloskey, Lorenz C. Hofbauer, Nuria Guanabens, Barbara Obermayer-Pietsch, Stuart H. Ralston, Richard Eastell, Jessica Pepe, Andrea Palermo, Bente Langdahl
Summary: Discontinuation of denosumab results in increased bone turnover, rapid bone loss, and risk of multiple vertebral fractures in some patients. Prior bisphosphonate therapy or subsequent antiresorptive treatment may help mitigate the biochemical rebound phenomenon after denosumab discontinuation.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Article
Computer Science, Hardware & Architecture
Lihua Yan, Jinrong Lu, Shouxiang Zhao
Summary: Mental perception drives the development of clinical remote sensor networks in urban areas, providing key applications and challenges for the healthcare field. These challenges are exacerbated by resource shortages at remote sensor network sites, but various methods are used to address the current issues.
MICROPROCESSORS AND MICROSYSTEMS
(2021)
Article
Urology & Nephrology
Ricardo Neto, Luciano Pereira, Juliana Magalhaes, Janete Quelhas-Santos, Sandra Martins, Catarina Carvalho, Joao Miguel Frazao
Summary: The study found that in CKD patients, high bone turnover is associated with worse renal function, lower serum calcium, and higher levels of intact parathyroid hormone and fibroblast growth factor-23. On the other hand, patients with low bone turnover presented with higher levels of sclerostin but lower levels of DKK1 and sRANKL.
CLINICAL KIDNEY JOURNAL
(2021)
Review
Endocrinology & Metabolism
Swati Rajput, Aditya Dutta, Singh Rajender, Ambrish Mithal, Naibedya Chattopadhyay
Summary: In this meta-analysis, the effectiveness of anti-resorptive therapies (bisphosphonates and denosumab) in preventing/treating bone loss and hypercalcemia in patients with primary hyperparathyroidism (PHPT) was investigated. The results showed that anti-resorptives significantly increased bone mineral density (BMD) at the lumbar spine and femoral neck, increased serum parathyroid hormone (PTH), and decreased serum calcium levels. Bisphosphonates only increased BMD at the lumbar spine, while denosumab increased BMD at both the lumbar spine and femur neck. Alendronate significantly improved bone loss and hypercalcemia in PHPT patients, without altering PTH and calcium levels.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Review
Medicine, General & Internal
Athanasios D. Anastasilakis, Elena Tsourdi, Gaia Tabacco, Anda Mihaela Naciu, Nicola Napoli, Fabio Vescini, Andrea Palermo
Summary: The study found that there is currently insufficient data to prove the significant impact of bone therapies on glucose metabolism in diabetic patients. It is uncertain whether antiosteoporotic drugs have different effects on fracture incidence between diabetic and nondiabetic patients. More research is needed to address these issues and provide stronger recommendations.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Nutrition & Dietetics
Laurent Maimoun, Safa Aouinti, Marion Puech, Patrick Lefebvre, Melanie Deloze, Pascal de Santa Barbara, Jean-Paul Cristol, Severine Brabant, Thomas Gautier, Marius Nedelcu, Eric Renard, Marie-Christine Picot, Denis Mariano-Goulart, David Nocca
Summary: Bariatric surgery leads to bone loss, and this study found that bone turnover increased following sleeve gastrectomy, resulting in reduced bone mineral density in the hip region.
Article
Endocrinology & Metabolism
L. N. Raborn, A. B. Burke, D. H. Ebb, M. T. Collins, L. B. Kaban, A. M. Boyce
Summary: Denosumab has shown potential as a treatment for fibrous dysplasia, but limited data exists on its safety and efficacy, especially after discontinuation. This case study provides insights into the duration of efficacy, surrogate treatment markers, and discontinuation effects of denosumab therapy for craniofacial FD. The importance of considering duration of efficacy when treating patients with FD and other nonresectable skeletal neoplasms that require long-term management is highlighted.
OSTEOPOROSIS INTERNATIONAL
(2021)
Article
Medicine, General & Internal
Ryszard Plinta, Mariola Czajkowska, Magdalena Pisula, Anna Brzek, Andrzej Knapik, Magdalena Olszanecka-Glinianowicz, Violetta Skrzypulec-Plinta
Summary: This study investigated the effects of regular fitness training, sex hormones, and selected bone turnover markers on sclerostin levels in young women. The results showed that regular fitness training, sex hormones, vitamin D, iPTH, β-CTx, and osteocalcin did not influence circulating sclerostin levels in young women.
ARCHIVES OF MEDICAL SCIENCE
(2023)